ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations

With an upside potential of 121.45%, ADMA Biologics, Inc. (NASDAQ:ADMA) ranks among the stocks under $20 that will explode. The company is navigating a sharp divide between bullish analyst sentiment and mounting legal scrutiny tied to allegations from earlier this year. On June 10, 2026, Raymond James analyst Ryan Deschner resumed coverage of ADMA Biologics, […]

Read on WOBR AI →